8-K: Surmodics to be Acquired by GTCR for $43.00 Per Share in Cash

Surmodics, a medical device and in vitro diagnostics company, has agreed to be acquired by GTCR for $43.00 per share in cash, valuing the company at approximately $627 million.

Summary

• Surmodics, Inc. has entered into a definitive agreement to be acquired by GTCR, a private equity firm.
• GTCR will acquire all outstanding shares of Surmodics for $43.00 per share in cash.
• The total equity valuation of the deal is approximately $627 million.
• The per-share acquisition price represents a 41.1% premium to Surmodics' 30-trading day volume-weighted average closing price through May 28, 2024.
• The Surmodics Board of Directors has unanimously approved the transaction and recommends that stockholders vote in favor of the deal.
• The transaction is expected to close in the second half of calendar year 2024.
• The deal is subject to customary closing conditions, including shareholder and regulatory approvals.
• The acquisition will be financed through a combination of committed equity from GTCR and committed debt financing.
• Upon completion of the transaction, Surmodics will become a privately held company and its stock will be delisted from Nasdaq.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the substantial premium offered to shareholders and the strategic partnership with GTCR. The language used by management is optimistic about the future prospects of the company under new ownership. However, there are some risks and uncertainties associated with the transaction, which prevents a perfect score.

Positives

• The acquisition provides Surmodics shareholders with immediate value creation at a substantial premium.
• GTCR is considered an ideal partner due to its expertise in the healthcare sector.
• The transaction is expected to position Surmodics for continued growth and value creation.
• The deal provides a clear exit strategy for shareholders at a premium.

Negatives

• Surmodics will be delisted from Nasdaq and become a privately held company.
• The transaction is subject to customary closing conditions, including shareholder and regulatory approvals, which could potentially delay or prevent the deal from closing.

Risks

• The transaction may not be completed within the anticipated timeframe or at all.
• Shareholder approval may not be obtained.
• Required regulatory approvals may not be secured.
• GTCR's financing may not become available.
• Limitations on remedies in the merger agreement may prevent Surmodics from enforcing GTCR's obligations.
• The announcement or pendency of the transaction may negatively impact Surmodics' business, operating results, or stock price.
• The merger agreement places limitations on Surmodics' ability to operate its business or engage in alternative transactions.
• The transaction may involve unexpected costs, liabilities, or delays.
• There are risks related to pending and future litigation.

Future Outlook

The transaction is expected to close in the second half of calendar year 2024, subject to customary closing conditions. Upon completion, Surmodics will be a privately held company.

Management Comments

• Gary Maharaj, President and CEO of Surmodics, Inc., stated that the transaction enables shareholders to realize immediate value creation with a substantial premium.
• Gary Maharaj also expressed confidence that the transaction will position the company to continue to deliver compelling benefits for physicians, patients and customers.
• Sean Cunningham, Managing Director and Head of Healthcare at GTCR, stated that Surmodics is well-positioned for attractive, long-term growth and value creation.
• Sean Cunningham also mentioned that GTCR looks forward to partnering with the Surmodics team to expand the company's offering and broaden its reach.

Industry Context

This acquisition reflects the ongoing trend of private equity firms investing in the healthcare and medical technology sectors. GTCR's expertise in healthcare and healthcare technology makes this a strategic move for both companies. The acquisition also highlights the value of companies with strong customer relationships and a history of developing innovative medical technologies.

Comparison to Industry Standards

• The 41.1% premium offered by GTCR is significant, suggesting a strong valuation of Surmodics compared to its recent trading performance.
• Comparable acquisitions in the medical device and diagnostics space often involve premiums, but the specific percentage varies based on the target company's growth prospects, market position, and financial health.
• The deal structure, involving a combination of equity and debt financing, is typical for private equity acquisitions.
• The transaction's timeline, with an expected closing in the second half of 2024, is consistent with the typical timeframe for similar deals, which often require several months for regulatory and shareholder approvals.

Corporate Governance

Stakeholder Impact

• Shareholders will receive a substantial premium for their shares.
• Employees may experience changes in their roles and responsibilities as the company transitions to private ownership.
• Customers and suppliers may see changes in their relationships with Surmodics as the company integrates with GTCR's portfolio.
• Creditors may be impacted by the change in ownership and financing structure.

Next Steps

• Surmodics will file a proxy statement with the SEC.
• Surmodics will mail the proxy statement to shareholders.
• Surmodics will hold a special meeting for shareholders to vote on the transaction.
• The parties will seek required regulatory approvals.
• The transaction is expected to close in the second half of 2024.

Key Dates

Keywords

acquisition, merger, GTCR, Surmodics, medical devices, in vitro diagnostics, private equity, shareholders, premium, delisting